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Supplementary Methods 
DNA-Encoded Antibody Libraries (DEAL) Technique 
The critical technique upon which this study is based is the DNA-encoded antibody 
library (DEAL) method, which has been reported elsewhere by our group1. When DEAL is 
utilized to measure proteins, it is used as follows (Supplementary Fig. 1).  Capture antibodies 
(CAs) against the protein of interest are chemically labeled with single-stranded DNA (ssDNA) 
oligomers, yielding ssDNA-CA conjugates.  The coupling reaction is accomplished using 
succinimidyl 4-formylbenzoate (SFB, Solutink) and Succinimidyl 4-hydrazinonicotinate acetone 
hydrazone in N,N-dimethylformamide (DMF) (SANH, Solulink) as conjugation agents to link 
amine termini on DNA  oligomers to the amine side-groups of proteins1. A size-exchange 
column is used to purify the product by removing excess unreacted DNA molecules. Separately, 
the complementary ssDNA oligomers are deposited in a barcode pattern on a poly-L-lysine-
coated glass slide using microchannel-guided patterning (details described in Supplementary 
Fig. 3). At the beginning of a DEAL protein assay, incubation of ssDNA-CA conjugates with the 
complementary spatially-patterned ssDNA array assembles the CAs onto those specific sites 
through DNA hybridization. This step transforms the DNA microarray into an antibody 
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microarray that is ready for a protein sandwich assay. Biological samples (i.e. plasma isolated 
from human whole blood) can be applied onto the CA microarray and antigens can be captured. 
Finally, detection antibodies and/or fluorescent read-out probes are introduced sequentially to 
complete the immuno-sandwich assay. DNA oligomer sequences are chosen with appropriate 
melting temperatures to optimize room-temperature hybridization to complementary strands 
while minimizing cross-hybridization (<5% in fluorescence signal). 
 
 
Serum Protein Biomarker Panels and Oligonucleotide Labels    
The protein panels used in the cancer-patient serum experiment (panel 1) and finger-prick 
blood test (panel 2), the corresponding DNA codes, and their sequences are summarized in 
Supplementary Table 1 and 2. These DNA oligomers were synthesized by Integrated DNA 
Technologies (IDT), and purified by high pressure liquid chromatography (HPLC). The quality 
was confirmed by mass spectrometry. 
 
Supplementary Table 1. List of protein panels and corresponding DNA codes.  
 
DNA-code Human Plasma Protein     Abbreviation  
 
Panel (1) 
 
 
Supplementary Figure 1  Schematic depiction of multi-parameter detection of proteins in 
integrated microfluidics using the DNA-Encoded Antibody Library (DEAL) technique.  
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A/A’  Interferon-gamma      IFN-γ 
B/B’  Tumor necrosis factor-alpha     TNF-α 
C/C’  Interleukin-2        IL-2 
D/D’  Interleukin-1 alpha      IL-1α 
E/E’  Interleukin-1beta      IL-1β 
F/F’  Transforming growth factor beta    TGF-β 
G/G’  Prostate specific antigen (total)    PSA 
H/H’  Interleukin-6      IL-6 
I/I’  Interleukin-10      IL-10 
J/J’  Interleukin-12      IL-12 
K/K’  Granulocyte-macrophage colony stimulating factor    GM-CSF 
L/L’  Monocyte chemoattractant  protein -1    MCP-1 
M/M’  Blank control/reference 
 
 
Panel (2) 
 
AA/AA’  Interleukin-1beta      IL-1β 
BB/BB’  Interleukin-6      IL-6 
CC/CC’  Interleukin-10      IL-10 
DD/DD’  Tumor necrosis factor-alpha     TNF-α 
EE/EE’  Complement Component 3     C3 
FF/FF’  C-reactive protein      CRP 
GG/GG’  Plasminogen      Plasminogen 
HH/HH’  Prostate specific antigen (total)    PSA 
 
 
Supplementary Table 2.  List of DNA sequences used for spatial encoding of antibodies 
Sequence 
Name Sequence) 
Tm (50mM  
NaCl) OC 
A 5'- AAA AAA AAA AAA AAT CCT GGA GCT AAG TCC GTA-3' 57.9 
A' 5' NH3- AAA AAA AAA ATA CGG ACT TAG CTC CAG GAT-3' 57.2 
B 5'-AAA AAA AAA AAA AGC CTC ATT GAA TCA TGC CTA -3' 57.4 
B' 5' NH3AAA AAA AAA ATA GGC ATG ATT CAA TGA GGC -3' 55.9 
C 5'- AAA AAA AAA AAA AGC ACT CGT CTA CTA TCG CTA -3' 57.6 
C' 5' NH3-AAA AAA AAA ATA GCG ATA GTA GAC GAG TGC -3' 56.2 
D 5'-AAA AAA AAA AAA AAT GGT CGA GAT GTC AGA GTA -3' 56.5 
D' 5' NH3-AAA AAA AAA ATA CTC TGA CAT CTC GAC CAT -3' 55.7 
E 5'-AAA AAA AAA AAA AAT GTG AAG TGG CAG TAT CTA -3' 55.7 
E' 5' NH3-AAA AAA AAA ATA GAT ACT GCC ACT TCA CAT -3' 54.7 
F 5'-AAA AAA AAA AAA AAT CAG GTA AGG TTC ACG GTA -3' 56.9 
F' 5' NH3-AAA AAA AAA ATA CCG TGA ACC TTA CCT GAT -3' 56.1 
G 5'-AAA AAA AAA AGA GTA GCC TTC CCG AGC ATT-3' 59.3 
G' 5' NH3-AAA AAA AAA AAA TGC TCG GGA AGG CTA CTC-3' 58.6 
H 5'-AAA AAA AAA AAT TGA CCA AAC TGC GGT GCG-3' 59.9 
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H' 5' NH3-AAA AAA AAA ACG CAC CGC AGT TTG GTC AAT-3' 60.8 
I 5'-AAA AAA AAA ATG CCC TAT TGT TGC GTC GGA-3' 60.1 
I' 5' NH3-AAA AAA AAA ATC CGA CGC AAC AAT AGG GCA-3' 60.1 
J 5'-AAA AAA AAA ATC TTC TAG TTG TCG AGC AGG-3' 56.5 
J' 5' NH3-AAA AAA AAA ACC TGC TCG ACA ACT AGA AGA-3' 57.5 
K 5'-AAA AAA AAA ATA ATC TAA TTC TGG TCG CGG-3' 55.4 
K' 5' NH3-AAA AAA AAA ACC GCG ACC AGA ATT AGA TTA-3' 56.3 
L 5'-AAA AAA AAA AGT GAT TAA GTC TGC TTC GGC-3' 57.2 
L' 5' NH3-AAA AAA AAA AGC CGA AGC AGA CTT AAT CAC-3' 57.2 
M 5'-Cy3-AAA AAA AAA AGT CGA GGA TTC TGA ACC TGT-3' 57.6 
M' 5' NH3-AAA AAA AAA AAC AGG TTC AGA ATC CTC GAC-3' 56.9 
AA' 5' NH3-AAAAAAAAAAGTCACAGACTAGCCACGAAG-3' 58 
BB 5'-AAAAAAAAAAGCGTGTGTGGACTCTCTCTA-3' 58.7 
BB' 5' NH3-AAAAAAAAAATAGAGAGAGTCCACACACGC-3' 57.9 
CC 5'-AAAAAAAAAATCTTCTAGTTGTCGAGCAGG-3' 56.5 
CC' 5' NH3-AAAAAAAAAACCTGCTCGACAACTAGAAGA-3' 57.5 
DD 5'-AAAAAAAAAAGATCGTATGGTCCGCTCTCA-3' 58.8 
DD' 5' NH3-AAAAAAAAAATGAGAGCGGACCATACGATC-3' 58 
EE 5'-AAAAAAAAAAGCACTAACTGGTCTGGGTCA-3' 59.2 
EE' 5' NH3-AAAAAAAAAATGACCCAGACCAGTTAGTGC-3' 58.4 
FF 5'-AAAAAAAAAATGCCCTATTGTTGCGTCGGA-3' 60.1 
FF' 5' NH3-AAAAAAAAAATCCGACGCAACAATAGGGCA-3' 60.1 
GG 5'-AAAAAAAAAACTCTGTGAACTGTCATCGGT-3' 57.8 
GG' 5' NH3-AAAAAAAAAAACCGATGACAGTTCACAGAG-3' 57 
HH 5'-AAAAAAAAAAGAGTAGCCTTCCCGAGCATT-3' 59.3 
HH' 5' NH3-AAAAAAAAAAAATGCTCGGGAAGGCTACTC-3' 58.6 
 
* All amine-terminated strands were linked to antibodies to form DNA-antibody conjugates using SFB/SANH coupling 
chemistry as described by R. Bailey et al.1 Codes AA-HH were used in the experiment which examined fresh whole blood from a 
healthy volunteer. Codes A-M were used for the molecular analyses of cancer patient serum samples.   
 
All matched antibody pairs and standard proteins (recombinants) were received from 
eBioscience except those described below. The antibody pairs for human C3 and CRP were 
received from Abcam. Their recombinants were from Sigma. The antibody pair and recombinant 
protein of human plasminogen were received from Molecular Innovations. The antibody pair for 
PSA were received from Biodesign. The PSA recombinant was from R&D Systems. The capture 
and detection antibodies for human hCG were received from Abcam and Chromoprobe, 
respectively. The antibody pair and the recombinant of human GM-CSF were both received from 
BD biosciences.  All oligonucleotides were synthesized by Integrated DNA Technologies.   
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Cross-reactivities of Oligonucleotide Labels  
A full orthogonality analysis was performed to quantitate the cross-hybridization between 
the stripes within the DEAL barcode assays. On a barcode array chip, thirteen strands of coding 
ssDNA (A-M) were patterned. Then, a 13-
well PDMS slab was placed onto the 
barcode chip and in each well a solution 
containing only one kind of 
complementary ssDNA from A’-M’ was 
added. All these complementary strands 
were labeled with Cy3 and the successful 
hybridization can be visualized by 
fluorescence using a 532nm laser 
excitation. The result (Supplementary 
Fig. 2) indicates negligible cross-
hybridization across the entire panel of 
DNA codes used in our DEAL barcode 
assay. 
Patterning of Barcode Arrays   
Using the microchannel-guided flow-patterning approach (Supplementary Fig. 3), we 
fabricated DEAL barcode arrays that were ~10-fold denser than conventional microarrays. 
Microcontact printing can generate high density arrays of biomolecules with spot sizes of a few 
micrometers (   ms)2, 3, but extending stamping to large numbers of biomolecules is awkward 
because of the difficulty in aligning multiple stamps to produce a single microarray. Direct 
microfluidics-based pattering of proteins has been reported, but DNA flow-patterning with 
sufficient loading remains less successful compared to conventional spotting methods4, 5. 
In the flow patterning process, a polydimethylsiloxane (PDMS) mold containing 13-20 
parallel microfluidic channels, with each channel conveying a different biomolecule capture 
agent, was used.  The number of channels could readily be expanded to include 100 or more 
different capture agents. Poly-amine coated glass surfaces permitted significantly higher DNA 
loading than do more traditional aminated surfaces, with a corresponding increase in assay 
 
 
Supplementary Figure 2.  Cross-hybridization 
check for all 13 DNA oligomer pairs that were used 
for encoding the registry of antibody barcode 
arrays.  
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sensitivity (Supplementary Fig. 4). DNA “bars” of 2 micrometers in width could be 
successfully patterned.  
In the present study, a 20-micrometer (   m) channel width was chosen because the 
fluorescence microarray scanner utilized has a resolution of 5  m. The fabrication details are as 
follows. 
Mold fabrication.  The microfluidic-patterning chips were made by molding a PDMS 
elastomer from a master template, which was prepared using photolithography to create a 
photoresist pattern on a Si wafer. An alternative was to make a silicon “hard” master by 
transferring the photolithographically-defined pattern into the underlying silicon wafer using a 
deep reactive ion etching (DRIE) process6. The first method offers rapid prototyping, while the 
second method yields a robust and reusable mold, permitting higher throughput chip fabrication.  
PDMS patterning chip fabrication.  A polydimethylsiloxane (PDMS) elastomer slab was 
fabricated by casting the Sylgard® 184 wet PDMS  (prepolymer:curing agent = 10:1 (w/w)) onto 
 
Supplementary Figure 3. Microchannel-guided flow patterning of DEAL barcode arrays. (a) 
Depiction of the procedure. Each DNA bar is 20   m wide and spans the dimensions of the glass 
substrate. (b) Integration of a DEAL barcode-patterned glass slide with microfluidics for multiplexed 
protein assays. (c) Mask design of a 13-channel barcode. A-M denotes the flow channels for the 
different DNA molecules. (d) Validation of successful patterning of DNA molecules by specific 
hybridization of oligomer A to its fluorescent complementary strand A’. The primary strands B and 
C were pre-tagged with red and green dyes as references.  
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the molds described above followed by a curing step at 80oC for 50min. This slab peeled off 
from the mold was bonded onto a glass surface, which provided the base walls for the flow 
channels. Prior to bonding, the glass surface was pre-coated with the polyamine polymer, poly-
L-lysine (Sigma-Aldrich), to increase DNA loading. The coating process is described 
elsewhere18. The number of microfluidic channels determines the size of the barcode array. In 
the present work, the PDMS chip, as shown in Supplementary Fig. 3c, contained 13 to 20 
parallel microchannels designed to cover a large area (3cm×2cm) of the glass slide with the 
DNA barcode microarray.  
DEAL Barcode patterning. Solutions, each containing a different strand of primary DNA 
oligomers prepared in 1x PBS buffer, were flowed into each of the microfluidic channels. Then, 
the solution-filled chip was placed in a desiccator to allow solvent (water) to evaporate 
completely through the gas-permeable PDMS, leaving the DNA molecules behind. This process 
took from several hours to overnight to complete. Last, the PDMS elastomer was removed from 
the glass slide, and the barcode-patterned DNA was fixed to the glass surface by thermal 
treatment at 80oC for 4 hours, or by UV cross-linking. Potassium phosphate crystals precipitate 
during solution evaporation, but are readily removed by rapidly dipping the slide in deionized 
 
Supplementary Figure 4. Effects of polylysine coating on DEAL assay. a. Schematic illustration 
of polylysine coating for increased loading of DNA oligomer codes. B. Fluorescence images 
showing a comparative study of the measurement of three human cytokines (IFN-γ, TNF-α and 
IL-2) using substrates coated with amino-silane and polylysine, respectively. 
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water prior to bonding the blood-assay chip to the slide.  This did not affect the quality of the 
DNA barcode arrays.   
The DEAL barcode chip renders a high density array for multiplexed protein measurements. 
 
 
Supplementary Figure 5. Increased sensitivity observed in immunoassays run on DEAL 
barcode arrays. a. Concentration-dependent fluorescence signal for the detection of three human 
cytokines (A: IFN-γ, B: TNF-α, C: IL-2, O: negative control) using a DEAL barcode array. The bar 
width is 20   m. b. Quantitation of fluorescence intensity vs. TNF-α concentration. c. 
Measurements of individual proteins, IFN-γ and IL-2, reveal no distinguishable cross-reactivity.  d. 
Comparison of the microfluidics flow-patterned DEAL microarrays with DEAL microarrays 
patterned using a conventional DNA pin-spotting method. The spot size is ~150-200   m. e. 
Fluorescence line profiles for the DEAL barcode array in a and the pin-spotted array in d at 
different protein concentrations.  The curves were amplified in the y-coordinates for better 
visualization.     
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Moreover, it also demonstrates a marked improvement in sensitivity as compared to 
conventional pin-spotted microarrays (Supplementary Fig. 5). A side-by-side comparison study 
was performed by running DEAL assays on three cytokines under identical conditions. Using the 
microchanne-guided flow patterning method, a glass slide was patterned with DNA oligomers A, 
B, C and a blank control O. Each bar was 20   m in width. The DNA solutions were all 50-100  M. 
The pin-spotted array, with a typical spot size of 150-200   m, was printed at the Institute for 
Systems Biology at 100  M concentration. Six sets of spots were printed corresponding to 
oligomers  A, B, C, D, E, and F. Poly-l-lysine coated slides were used for both types of arrays.  
Before the DEAL assay, the capture antibodies were conjugated to DNA oligomer codes 
as follows: A’ to IFN-γ, B’ to TNF-α, and C’ to IL-2. Protein standards were diluted in 1% 
BSA/PBS solution at concentrations ranging from 1fM to 1nM. The incubation time for each 
step (blocking, conjugate hybridization, sample binding, detection-antibody binding, and 
fluorescent-molecule binding) was 30min.  The results (Supplementary Fig. 5b) reveal that the 
DEAL barcode array sensitivity is similar to the projected sensitivity limit of the commercial 
ELISA assay (~10pg/mL, or 0.8pM; eBioscience).  Taking the example of the TNF-α assay, the 
detection sensitivity of the DEAL barcode array (better than 1 pM) is substantially improved 
over the 10-100pM limit found for the microarrays spotted using conventional methods 
(Supplementary Fig. 5d). Therefore, the DEAL barcode array combines ELISA-like sensitivity 
with a high degree of multiplexing for protein measurements.   
A difference between these two platforms – barcode array and pin spotted array – is the 
feature size. The barcode array has a line-width of 20  m, whereas the spot diameter in 
conventional arrays is more than 150  m.  These results are consistent with a recent report which 
demonstrated that DNA microarrays with smaller spot sizes could detect DNA with increased 
sensitivity7.  
The ELISA-like sensitivity of the DEAL barcode assays is key for realizing the 
multiplexed measurement of human plasma proteins in blood. The human plasma proteome is 
comprised of three major classes of proteins – classical plasma proteins, tissue leakage proteins, 
and cell-cell signaling molecules (cytokines and chemokines). Cell-cell signaling molecules are 
biologically informative in a variety of physiological and pathological processes, i.e. tumor host 
immunity and inflammation.  In human plasma proteome, the concentration range of plasma 
proteins spans 12 orders of magnitude, and the lowest end is approximately at the detection limit 
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of mass spectrometry – a high-throughput protein profiling technique. The state-of-the-art for 
clinical protein measurements is still the typically low-throughput ELISA assay. The high 
performance of the DEAL barcode chip, including its increased sensitivity, is a key to realizing 
highly multiplexed measurements of a panel of proteins from small quantities of clinical blood 
samples.    
Fabrication of IBBCs 
The fabrication of the IBBCs was accomplished through a two-layer soft lithography approach8, 
9. A representative chip design is shown in Supplementary Fig. 6. The silicon master for the 
control layer (red) was fabricated by exposing a spin-coated SU8 2010 negative photoresist film 
(~20um thickness). Prior to molding, the master was silanized in a trimethylchlorosilane(TMCS) 
vapor box for 20min. A mixture of GE RTV 615 PDMS prepolymer part A and part B (5:1) was 
prepared, homogenized, and then applied onto the control layer master. After degassing for 
15min, the PDMS was cured at 80oC for 50 min. The solidified PDMS chips were then cut off 
the master and the access holes were drilled with a 23 gauge stainless-steel hole punch.  
The flow-layer master (blue) was fabricated using SPR 220 positive photoresist. After 
exposure and development, the photoresist pattern was baked at 120oC in a convection oven to 
round the flow channels. The resultant flow layer was typically 15-20  m in thickness. 
Silanization using TMCS was performed right before applying the fluid PDMS prepolymer. 
Next, a mixture of GE RTV 615 PDMS part A and part B (20:1) was prepared, homogenized, 
 
Supplementary Figure 6.  AutoCAD design of an IBBC: flow layer in red; control layer in green. 
Underneath the PDMS microfluidic chip is a large-scale DNA bar-code array. 
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degassed, and then spun onto the flow layer master at 2000-3000 rpm for 1 min. It was cured at 
80oC for 30min, at which point the PDMS control layer was carefully aligned and placed onto 
the flow layer. Finally, an additional 60-min thermal treatment at 80oC was performed to bond 
the two PDMS layers together.  The bilayer chip was then peeled off of the flow-layer master 
and access holes were drilled.   
 The last assembly step was to bond the PDMS chip to the DEAL barcode slide (described 
in section 2) via thermal treatment at 80C for 4 hours, yielding a completed integrated blood 
barcode chip (IBBC). In this chip, the DEAL barcode stripes are orientated perpendicular to the 
microfluidic assay channels. The IBBC features a microfluidic biological fluid-handling module, 
specifically a whole blood separation unit, and a DEAL barcode array for highly multiplexed 
protein measurements. In a typical design, 8-12 identical blood separation and detection units 
were integrated on a single 2.5 cm x 7 cm chip.  
Execution of blood separation and multiparameter protein assay using IBBCs 
The compatibility of the DEAL technique with integrated microfluidics yielded rapid 
blood separations and reliable measurements of a panel of proteins. The experimental procedure 
is detailed below. 
a. Blocking: Prior to use of the IBBC, all microfluidic channels were blocked with the assay 
buffer solution (1% w/v BSA/PBS solution prepared by adding 98% pure Bovine Serum 
Albumin, Fraction V (Sigma) to 150 mM 1x PBS without calcium/magnesium salts (Irvine 
Scientific)) for 30-60minutes.  
b. DEAL formation (introducing conjugates): A solution containing all DNA-antibody 
conjugates was flowed through the assay channels of the IBBCs for ~30-45min, thus transformed 
the DNA barcode microarray into an antibody microarray, enabling the subsequent surface-
bound immuno-assay. The unbound conjugates were removed by flowing the assay buffer 
solution for 10 minutes. The DEAL-conjugate solution was prepared by mixing all synthesized 
conjugates in1% BSA/PBS with a final concentration of 5  g/mL. The DNA coding oligomers 
were pre-tested for orthogonality to ensure that cross-hybridization between non-complementary 
oligomer strands yielded a fluorescence intensity that did not exceed 5% of the complementary-
pair signal intensity.   
c. Collecting a finger-prick of blood:  Finger pricks were carried out using BD Microtainer 
Contact-Activated Lancets (purple lancet – for low volume, single blood drop). Blood was 
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collected with SAFE-T-FILL capillary blood collection tubes (RAM Scientific), which were pre-
filled with a 25 mM EDTA solution as discussed below. Two samples were prepared from the 
drop of whole blood.  
(i) Unspiked Blood Samples: The blood collection tube was pre-filled with 80   L of 25 mM 
EDTA solution, and then 10   L of fresh human blood was collected in the EDTA-coated 
capillary, dispensed into the tube and rapidly mixed by inverting a few times. 
(ii) Spiked Blood Samples: The blood collection tube was pre-filled with 40   L of 25 mM EDTA 
solution. Forty microliters of recombinant protein solution, containing all the protein standards, 
was added. Then, 2   L of 0.5 M EDTA was added to bring the total EDTA concentration up to 
25mM. Finally, 10   L of fresh human blood was collected in an EDTA-coated capillary, added to 
the tube and quickly mixed by inverting a few times. The final concentrations for all protein 
standards were ~10nM. However, the quality of these “standards” and the affinity of capture 
antibodies vary substantially. The purpose of spiking in protein standards was to contrast the 
signal at high protein concentrations with that of as-collected fresh whole blood. 
 d. Blood sample assay: These two blood samples were flowed into the IBBCs within 1 minute 
of collection. The plasma was quickly separated from blood cells within the chip, and the 
proteins of interest were captured in the downstream assay zone containing the DEAL barcode 
arrays. The entire process from finger prick to the completion of plasma protein capture was very 
rapid (<10 mins). Owing to the reduced diffusion barrier in a flowing microfluidic environment, 
the sample assay was executed within ten minutes. With regards to the cancer patient serum tests, 
the as-received serum samples (Asterand) were flowed into IBBCs without further treatment.  
e. Applying detection antibodies: A mixture of biotin-labeled detection antibodies was flowed 
into the microfluidic devices for ~30min to complete the DEAL assay. The detection-antibody 
solution contained biotinylated detection antibodies at ~5   M prepared in 1% BSA/PBS. 
Afterwards, unbound detection antibodies in the IBBCs were removed by flowing the assay 
buffer for 10 minutes. 
f. Fluorescence probes: For the cancer serum experiments, Cy5 fluorescent dye-labeled 
streptavidin and the reference, Cy3-labeled complementary ssDNA (DNA code M/M’), were 
mixed together and were then flowed into the IBBCs for 30min. Finally, the assay buffer was 
flowed for 10 minutes to remove unbound Steptavidin-Cy5. 
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g. Rinse: The PDMS blood chip device was removed from the DNA-patterned glass slide. The 
slide was immediately dipped 6 times each in the following solutions in order: 1% BSA/PBS 
solution, 1x PBS solution, ½ x PBS solution, deionized Millipore H2O. The slide was rinsed for a 
few seconds under a Millipore H2O stream, and then dried with a nitrogen gun. 
h. Optical readout: The slide was scanned by an Axon Instruments Genepix Scanner. The finest 
resolution (5  m) was selected. Two color channels (the green Cy3 channel and the red Cy5 
channel) were turned on to collect fluorescence signals.  
Consideration of microfluidic environment for rapid immunoassay   
In a micro-fluidic environment, at sufficiently high flow rates, diffusion is not limiting, 
and the rate at which a biological assay can be completed is determined by the kinetic parameters 
that describe the capture of the biomolecule by the surface-bound capture agent10. Under 
chemical equilibrium, the relative amount of biomolecule that is complexed to the surface-bound 
capture agent is given by: 
Keq = [biomolecule-CA complex] / [biomolecule in solution][Surface Bound CA] 
where Keq is the equilibrium constant.  For a given concentration of biomolecule, the surface-
bound assay sensitivity depends upon several factors, including:   
• The equilibrium constant, Keq: a large Keq corresponds to a large amount of the 
biomolecule-CA complex.  
• The concentration of surface-bound CA: we find that the sensitivity limits of the assay 
directly correlate with the concentration of surface-bound CA1. During microchannel-
guided flow-patterning of the DEAL barcode arrays, the glass surface was modified by 
treatment with poly-L-lysine (a poly-amine), yielding a three-dimensional matrix for 
DNA adsorption and markedly increasing the amount of DNA loading. Our DNA-loading 
density is estimated to be 6x1013molecules/cm2, an order of magnitude higher than 
typical loading densities on amino-silane coated glass slides.11 As a result, the protein 
detection sensitivity was improved by an order of magnitude, and the dynamic range was 
increased to 4 orders of magnitude, as compared with 2-3 orders of magnitude for the 
small-molecule amine (i.e. amino-propyl-triethoxyl silane, APTES) functionalized glass 
surface. The comparative study is shown in Supplementary Fig. 4. 
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• Feature size:  smaller feature sizes can lead to increased sensitivities.7 The feature sizes 
(20   m wide stripes) of DEAL barcode chips are substantially smaller than are generated 
using more traditional spotting methods (150   m diameter spots).   
Supplementary Data 
Blind test of hCG unknown serum samples 
Two unknown hCG 
serum samples have been 
measured in a blind test using 
DEAL barcode assay. These two 
samples were introduced along 
side with the eight standards of 
hCG-spiked serum on the same 
DEAL barcode chip. Fluorescent 
images (Supplementary Fig. 7 
inset: lower) were acquired at the 
same laser settings and 
quantified from 20 sets of 
barcodes. Using the standard 
curve of 200-   M DNA loading, 
we estimated the hCG 
concentration. The result is 
shown in the Supplementary 
Fig. 7 inset table, and compared 
to the test results from an outside independent laboratory (Labcorp; the test was requested by the 
Nanotechnology Characterization Laboratory at the National Cancer Institute). The DEAL 
barcode assay result is in reasonable agreement with Labcorp results.      
Protein Cross-Reactivities    
 
 
 
Supplementary Figure 7. Blind test hCG unknown samples. 
The black squares correspond to the 200mM DNA loading 
shown in Fig. 2 and the red squares show the statistical means 
of two unknowns. The insets show representative images of 
barcode assay results for two unknowns, plus a table showing 
the estimated concentrations measured from both DEAL 
barcode assay and an independent laboratory (Labcorp).   
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We assessed the level of cross-reactivity of each antigen with DEAL stripes that are not 
specific to that antigen. DNA-encoded capture antibodies and biotinylated detection antibodies 
for all 12 antigens were used as usual, but a distinct antigen (10nM) was added to each assay 
lane. Cy5-Streptavidin (red-flourescence tag) was added to visualize the extent of analyte 
capture. The reference marks (DNA strand M) were visualized in all lanes with fluorescent green 
Cy3-M’ DNA molecules. The 12 proteins showed a negligible extent of cross-reactivity 
(Supplementary Fig. 8), with typical photon counts under 2% compared to the correctly paired 
antigen-antibody complexes. Even at this low-level, most of these cross-talk signals were found 
to be due to degraded recombinants (protein standards) and did not appear reproducibly once a 
new recombinant was used. This 
minimal cross-talk was also validated 
in pin-spotted microarrays using the 
same set of primary DNA codes. This 
negligible cross-talk in our DEAL 
assays is largely attributable to the 
significant efforts we have taken to 
screen for orthogonal DNA pairs 
(Supplementary Tables 1 and 2). A 
non-fully orthogonal DNA pair leads 
to cross-hybridization, and resultant 
cross-reactivity in the DEAL protein 
assay.1    
Dilution curves for all proteins used in the DEAL barcode assay  
We performed assays on serial dilutions for all 12 proteins on the DEAL barcode chip 
Because each device allows a maximum of 12 parallel assays to be executed, we chose 6 lanes 
for cross-talk validation, leaving 6 lanes for dynamic range studies. As a result, we combined 2 
proteins in each assay lane (Supplementary Fig. 9a).  On the same chip, we assayed all proteins 
over the concentration range of 1nM - 1pM (except PSA and TGF-β: 5nM to 5pM), and 
quantified the fluorescence signal vs. concentration for all 12 antigens (Supplementary Fig. 9b). 
In this experiment, all concentrations were imaged using the Genepix scanner held at the same 
condition as described in the Method section. Apparently, the estimated sensitivity varies 
 
 
 
Supplementary Figure 8.  Cross-reactivity check for all 12 
proteins, for both barcode (left panel) and pin-spotted (right 
panel) microarrays. The green bars represent the reference 
stripe/spot – M. Each protein can be readily identified by its 
distance from the reference. The designation of proteins in 
the barcode is the same as in Figure 3 and 4. 
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substantially depending upon the antibodies being used, from ~0.3pM (e.g. IL-1β and IL-12) to 
30pM (TGF-β).  For example, the TGF-β antibody pair has a relatively lower binding affinity 
and a poorer detection limit in ELISA (according to the spec sheet, it is ~70pg/mL compared to 
5-10pg/mL for most other cytokines). Predictably, this gave rise to a poorer performance in the 
DEAL assay. Although these curves reflect the ability of the microfluidics-patterned DEAL 
assays to assess specific antigens over broad concentration ranges, the statistical variation is 
relatively large compared to a commercial ELISA assay.   
Standardized quantification of the patient serum DEAL barcode data   
Barcode signal quantitation was performed through a standardized process designed to 
prevent the possibility of arbitrary bias in manual image analysis.    First, the fluorescence from 
the barcodes was visualized under fixed conditions - using the Axon Genepix 4000B two-color 
laser microarray scanner with identical instrumental settings:  For 635 nm and 532 nm excitation 
lasers, respectively, the following settings were used: 100% and 33% laser power levels; 800 and 
700 for optical gain; 88 and 87 for  brightness and contrast. Second, the JPEG image exported 
from the Genepix 6.0 software resized to match the standard image generated from the exact 
barcode array mask design, and NIH imageJ was employed to generate an intensity line profile in 
 
 
Supplementary Figure 9. Dilution curves for 12 proteins measured using DEAL-based barcodes 
entrained within microfluidics channels. (a) Barcode images from one device showing minimal cross-
talk, and a series of standard antigens ranging from 1nM to 1pM for all 12 proteins (* the concentrations 
of PSA and TGF-β are 5x higher). (b) Quantitation of fluorescence intensity vs. concentration for all 12 
proteins. Error bars: 1SD 
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every assay channels and 
subchannels. Each data 
point in the line profie was 
averaged from 40 pixels 
(200  m) along the vertical 
direction.  Fourth, all the 
line profile DATA files 
were loaded into a custom-
written Excel macro that 
generated a spread sheet of 
the average intensities of 
all 13 bars (1 bar = 5 × 40 
pixels, or 25 × 200   m area) 
in each of 20 barcodes.  
The statistical analysis 
generated mean values and standard divisions (in Microcal Origin).  
For demonstrating the feasibility of using the NIH imageJ program, we performed a 
calibration by comparing the photocounts from the Genepix 6.0 and the brightness value 
quantitated from imageJ (Supplementary Fig. 10). A linear correlation (p<0.0001) exists if the 
intensity from imageJ is no higher than 90. The scale of brightness in red-green-blue (RGB) 
mode is 0-255, so each color has a brightness maximum at 85. A common baseline (~10) t is 
superimposed onto the red fluorescence signal, and so the real maximum  is ~90-100. The 
calibration demonstrates that it is valid to use imageJ to quantitate the DEAL barcode data.  We 
are pursuing a fully automated process for feature recognition, signal quantitation and 
concentration extraction.   
The mean values of measured protein levels for every patient were exported into a matrix 
for non-supervised clustering of patients. This was performed using the software Cluster and the 
heat map was generated from the software Treeview, both developed by the M. Eisen’s group. To 
assess the significance of two patient (sub)groups, the Student’s t-analysis was performed on 
selected proteins and all p-values  
 
Supplementary Figure 10. Comparison of fluorescence intensities 
quantitated using the genepix 6.0 software and the NIH imageJ 
program. It shows good linear correlation up to 85 (per pixel) where 
the imageJ quantitation begins to saturate.  
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Supplementary Figure 12. Quantitation of the fluorescence intensities of the results for 11 
prostate cancer patients (P01-P11). The proteins are shown in the same order as that described 
in Fig. 3a.   
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Supplementary Figure 11. Quantitation of the fluorescence intensities in the measurement of 11 
breast cancer patients (B01-B11). The proteins are shown in the same order as that described in 
Fig. 3a. 
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were calculated at significance level of 0.05 if not otherwise specified.   This standardized 
quantitation process diminished any possible biases in the manual quantitation processes, but 
was unable to identify and exclude interfering speckles and noises in the images. A dust particle 
atop a barcode can give rise to extremely bright scattering signal, thus causing large errors in 
quantitating this barcode.  In addition, several samples such as P04, P05, P10 and B10 exhibit 
significant bio-fouling and introduce a large non-specific background into quantitation. These 
issues remain to be solved in further development of DEAL barcode assay. 
Quantitation and Statistics of the barcodes for all patient sera are shown in 
Supplementary Fig. 11 and 12. The data for all proteins in these plots were shown in the same 
order as indicated in Figure 3a. 
ELISA validation of DEAL barcode assay  
Given our limited serum sample quantities, and the amount of material required for 
carrying out standard protein measurements, we could only perform strategic cross-validations of 
the DEAL barcode measurements.  PSA was the single protein that readily discriminated 
between breast and prostate cancer patients, and, in addition, clinical measurements of PSA 
levels for most of the prostate cancer patients were available through the serum vendor 
(Asterand).  Thus, for all 22 patient serum samples, we performed an Enzyme-link 
Immunosorbant Sandwich Assay (ELISA) for independently assessing the PSA levels.   
A comparative study of PSA measured by ELISA and by the DEAL barcode assays is 
shown in Figure 3c.  One set of ELISA data was collected using 96-well plate formats in our lab.  
A second set of ELISA data, for 8 of the prostate cancer patient serum samples, was measured in 
commercial (clinical) labs.   The DEAL barcode data is taken from Figure 3b. For our own 
ELISA measurements (Supplementary Fig. 13a), the first row was loaded with PSA standards 
at serial dilutions. 22 Serum samples and a negative control (buffer) were measured.   All three 
data sets are presented in Figure 3c, and are in good agreement with one another. The DEAL 
barcode assay detects the presence of PSA at 100% accuracy, but is less accurate relative to the 
ELISA tests in terms of quantitating small changes in concentration.  This may be due, in part, to 
slight variations in both our manual chip assembly procedures and in our manual assaying 
procedures. It may also be that the higher sensitivity and concentration range of the DEAL 
assays is accompanied by a reduction in accuracy.  We are in the process of fully automating 
both our microfluidics barcode patterning method, and our assay procedure.  Those advances 
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will allow us to more fully assess the trade-offs between the sensitivity and accuracy of the 
DEAL barcode arrays versus traditional ELISA formats.  
In comparison with the clinical ELISA results measured on fresher sera, our own ELISA 
measurements are generally lower in intensity.  This likely reflects the influence of long-time 
storage (>1year) and freeze/thaw cycles (>1 time).  The correlation between the ELISA and the 
DEAL barcode is analyzed using literature methods12. The R value is comparable to literature 
measurements that compare multiplexed assays against ELISA standards13. This good agreement 
between the standard ELISA and the DEAL barcode method with respect to the PSA 
measurements provides validation of IBBC for measuring proteins from human sera.  
 
Supplementary Figure 13. Validation of PSA detection using ELISA. a. Photo showing ELISA test 
we performed on PSA standards and 23 as-received serum samples. b. Correlation between ELISA 
(our lab) and the DEAL barcode assay. All DEAL tests were done in multiplex.  
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hypertension3+3=6T2cN0M0CaucasianMale / 47ProstateP11
hypertension, 11-20 cigs/day3+3=6T2aN0MXCaucasianMale/66ProstateP10
hypertension, atrial fibrillation4+3=7T3aN1MXCaucasianMale/78ProstateP09
1-5cigs/day3+3=6T2aNXMXAfrican Am.Male/72ProstateP08
gastroesophageal reflux3+4=7T3aN0M0CaucasianMale/60ProstateP07
chronic bronchitis, 11-20cigs/dayT3N0M0CaucasianMale/64ProstateP06
hypertension,11-20 cigs/day 4+4=8T3aNXMX CaucasianMale / 73ProstateP05
11-20 cigs/day 3+3=6T2bN0M0CaucasianMale / 55ProstateP04
hypertension 3+3=6 T2cN0M0CaucasianMale / 47ProstateP03
3+4=7T3bN0MXCaucasianMale / 64ProstateP02
4+3=7T2cNXM0CaucasianMale / 51ProstateP01
arterial hypertension T1NXM0CaucasianFemale/63BreastB11 
6-10cigs/day, hyperthyroid, hypertension, osteoarthritis T3N2MXHispanicFemale/63BreastB10
Coronary artery disease, cerebral atherosclerosisT4N0M0CaucasianFemale/83BreastB09
1-5 cigs/day, wine 200mL/dayT2NxM0CaucasianFemale/55BreastB08
hypertension, obesityT2N2M0CaucasianFemale/54BreastB07
T1NXM0AsianFemale/56BreastB06
arthritisT3N0MXCaucasianFemale/89BreastB05
hypertensionT2NXM0CaucasianFemale/72BreastB04
1-2 drinks/dayT1cNXM0CaucasianFemale/71BreastB03
T4N2M0 CaucasianFemale/79BreastB02
wine 200mL/dayT2N0M0CaucasianFemale/62BreastB01
OTHERS
GLEASONS 
SCORE
UICC STAGERACEGENDER/AGECANCER PATIENT
Medical records of cancer patients   
Full medical records were provided for all serum samples acquired from Asterand. The selected 
information is listed in Supplementary Table 3. Sample IDs were excluded for privacy 
protection.  
 
Supplementary Table 3.   Medical Record of cancer patients.  
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